Predicting prognosis and treatment response of breast cancer patients using expression and cellular localization of N-myristoyltransferase
AssigneeOneodrek Inc.
InventorAnuraag Shrivastav
Life of this patent
Estimating the term…
Abstract
High levels of nuclear NMT1 are associated with longer relapse free survival in ERα positive breast cancer patients. Both low levels of cytosolic and nuclear NMT1 correlated to very poor clinical outcomes. NMT2 also plays an important function in breast cancer signalling, regulated through phosphorylation. For example, NMT2 phosphorylation status is a key element in the progression of ER+ breast cancer cells. Specifically, nuclear localization of NMT2 is associated with poor outcomes in breast cancer patients.
Claims8
A method of determining the prognosis of a breast cancer patient comprising:
- extracting a cell sample from a breast tumor of a patient;
- determining the cellular localization of NMT2 in at least one cell of the cell sample;
- wherein if the at least one cell of the cell sample is positive for nuclear NMT2, the prognosis is poor, and
- if the at least one cell of the cell sample is negative for nuclear NMT2, the prognosis is good.
A method of determining the prognosis of a triple-negative breast cancer patient comprising:
- extracting a cell sample from a breast tumor of a patient;
- determining the cellular localization of NMT2 in at least one cell of the cell sample;
- wherein if the at least one cell of the cell sample shows positive nuclear localization of NMT2, the prognosis is poor.
Dependencies are inferred from the claim text.